In addition to qualitative PD‐L1 detection, one study revealed a correlation between the abundance of PD‐L1 in CTCs and the response to PD‐1/PD‐L1 blockade therapy in patients with advanced gastrointestinal tumors [150]. The gene discussed is CD274; the disease is digestive system neoplasm.